Beyond Menopause: Why Women's Metabolic Health Is a Lifelong Conversation

From PMOS to the menopause transition, understanding the hormonal and metabolic connections that shape women's health.

By Angela D. Mazza, DO, ABAARM, FAAMFM, ECNU

Does polyendocrinre metabolic ovarian syndrome (PMOS) [formerly known as polycystic ovary syndrome (PCOS)] disappear at menopause—or does it simply change how it shows up?

For decades, PC

OS has been viewed largely through the lens of reproductive health. Irregular menstrual cycles, elevated androgen levels, acne, and fertility challenges often dominate the conversation.

But what happens when the reproductive years end?

The hormonal landscape changes dramatically during menopause, yet some of the metabolic vulnerabilities associated with PCOS may persist long after menstrual cycles stop.

This raises an important question: Should we be thinking about women's endocrine health across the entire lifespan rather than focusing on individual reproductive stages?

That question is at the heart of my recent commentary published in Endocrine Practice, exploring the relationship between PCOS, menopause, and a proposed broader framework called polyendocrine metabolic ovarian syndrome (PMOS).

PCOS Is About More Than the Ovaries

PCOS affects multiple interconnected physiological systems. Although its diagnosis is traditionally based on reproductive and androgen-related features, its effects can extend far beyond the ovaries.

Many women with PCOS experience metabolic challenges, including:

• Insulin resistance and altered glucose regulation

• Increased risk of type 2 diabetes

• Dyslipidemia and other cardiometabolic risk factors

• Changes in body composition and adipose tissue function

• Chronic low-grade inflammation in some individuals

• 
  

Not every woman with PCOS experiences these complications, and their severity varies considerably.

Nevertheless, these associations remind us that PCOS is not exclusively a reproductive condition. It involves complex interactions among the ovaries, pancreas, adipose tissue, liver, and other endocrine systems.

And these systems do not stop interacting when menopause begins.

What Changes at Menopause?

Menopause marks the end of reproductive ovarian function, accompanied by substantial changes in estrogen and progesterone production.

For women with a history of PCOS, some familiar features may become less apparent. Menstrual irregularity is no longer a useful clinical marker after menopause, and androgen-related symptoms may change over time.

However, the disappearance of reproductive symptoms does not necessarily mean that underlying metabolic concerns have resolved.

Insulin resistance, unfavorable lipid patterns, and other cardiovascular risk factors may persist into later life.

At the same time, menopause itself is associated with changes in body fat distribution, insulin sensitivity, and lipid metabolism.

The combination of a prior PCOS history and the physiological changes of menopause may create a particularly important opportunity for individualized metabolic assessment.

Importantly, this does not mean that every woman with PCOS will develop metabolic disease after menopause. It means that reproductive history may provide valuable information when evaluating long-term health.

Introducing the PMOS Perspective

In my recent Endocrine Practice commentary, I explore the concept of polyendocrine metabolic ovarian syndrome (PMOS) as a way to encourage a broader, lifespan-based understanding of the endocrine and metabolic features traditionally associated with PCOS.

PMOS is a proposed conceptual framework, not an established diagnosis or replacement for current PCOS diagnostic criteria.

The idea is to recognize that endocrine dysfunction does not always fit neatly into one organ system or one stage of life.

The ovaries communicate continuously with the brain, adrenal glands, pancreas, liver, adipose tissue, and other metabolic systems.

Changes in one part of this network may influence others.

This is the foundation of systems endocrinology: understanding how hormonal and metabolic pathways interact rather than evaluating each hormone or organ in isolation.

From this perspective, menopause is not necessarily the end of the PCOS story. It may represent a new chapter in a woman's endocrine and metabolic health.

Why This Matters for Healthy Aging

One of the most important implications of this broader perspective is the opportunity to identify and address metabolic risk earlier.

For women with a history of PCOS, ongoing clinical assessment may include attention to:

Glucose regulation. Insulin resistance and type 2 diabetes risk may remain relevant beyond the reproductive years.

Cardiovascular health. Blood pressure, lipid profiles, and other cardiovascular risk factors deserve individualized evaluation.

Body composition. Changes in muscle mass, visceral adiposity, and metabolic function may become increasingly important during midlife.

Menopausal symptoms. Vasomotor symptoms, sleep disturbances, and genitourinary symptoms should be evaluated and treated according to each woman's needs and risk profile.

Lifestyle and prevention. Nutrition, resistance exercise, physical activity, sleep, and other sustainable health behaviors remain essential components of long-term metabolic care.

These considerations are not unique to women with PCOS. However, a history of PCOS may provide additional context for determining which areas deserve closer attention.

The goal is not to medicalize menopause or assume that every woman is destined to develop metabolic complications.

Instead, it is to recognize opportunities for prevention and personalized care.

Moving Beyond a One-Size-Fits-All Approach

Women's endocrine health is dynamic.

Hormonal patterns change during puberty, reproductive life, perimenopause, menopause, and aging. Yet the underlying metabolic systems remain interconnected throughout these transitions.

A woman who experienced irregular menstrual cycles and insulin resistance in her twenties may have very different symptoms in her fifties, but her earlier endocrine history may still be clinically relevant.

Understanding those connections can help clinicians move beyond treating isolated laboratory values or symptoms.

It encourages us to ask broader questions:

What metabolic patterns have persisted over time? How have hormonal transitions influenced those patterns? And what can we do now to support healthier aging?

These are the questions that make a lifespan-based approach to women's health so important.

The Bigger Picture

Menopause changes the hormonal landscape, but it does not erase a woman's endocrine history.

As our understanding of PCOS and metabolic health continues to evolve, we have an opportunity to rethink how we approach women's health across the lifespan.

The proposed PMOS framework is intended to encourage that conversation—not to replace established diagnoses, but to broaden how we think about the interconnected nature of endocrine and metabolic health.

Ultimately, the goal is simple: to move beyond isolated symptoms and reproductive milestones toward a more comprehensive, individualized approach to lifelong wellness.

Because women's metabolic health deserves attention at every age.

Featured Publication

This article highlights concepts discussed in my commentary published in Endocrine Practice examining PCOS, the proposed PMOS framework, and the menopause transition.

The work was also recently featured by the American Academy of Anti-Aging Medicine (A4M).

Read the A4M feature:https://blog.a4m.com/beyond-menopause-why-pcos-pmos-may-require-a-lifespan-approach-to-metabolic-health/

About the Author

Dr. Angela D. Mazza is a triple board-certified endocrinologist and founder of the Metabolic Center for Wellness in Oviedo, Florida. Her clinical and academic work focuses on thyroid disorders, hormonal health, metabolic dysfunction, and systems endocrinology.

This article is intended for educational purposes and does not replace individualized medical evaluation or treatment.